H.C. Wainwright Thinks Clearside Biomedical’s Stock is Going to Recover
May 12 2022 - 06:31AM
TipRanks
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on
Clearside Biomedical (CLSD – Research Report) today and set a price
target of $10.00. The company's shares closed last Wednesday at
$1.45, close to its 52-week low of $1.31. According to
TipRanks.com, Chen is ranked 0 out of 5 stars with an average
return of -11.4% and a 28.3% success rate. Chen covers the
Healthcare sector, focusing on stocks such as Ortho Clinical
Diagnostics Holdings, Interpace Diagnostics Group, and HTG
Molecular Diagnostics. The word on The Street in general, suggests
a Strong Buy analyst consensus rating for Clearside Biomedical with
a $9.67 average price target, implying a 515.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-clearside-biomedicals-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Jan 2023 to Feb 2023
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Feb 2022 to Feb 2023